Yale Cancer Center scientists show immunotherapy drug can help patients with metastatic melanoma

When melanoma turns metastatic, it spreads to the brain in more than 40% of patients. Published today in the Journal of Clinical Oncology (JCO), a study by Yale Cancer Center researchers show a checkpoint inhibitor immunotherapy drug has meaningful benefit for these patients.

Provided by EUPB - Read the full story at the source site.
Read The Full Story

Top News